FDA Inspection
Eosera, Inc.Eosera, Inc. – FDA Inspection, Jan 17, 2020
Record Details
This FDA Inspection record concerns Eosera, Inc., with an inspection on January 17, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Eosera, Inc.
- Inspection Date
- January 17, 2020
- Product Type
- Drugs
View Company Profile
ID · 3221668e-fad4-4ca7-b173-8cba754bd210
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1115592
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Enforcement
- Warning Letter
FDA Citations
5- 21 CFR 211.110(a)Control procedures to monitor and validate performance
- 21 CFR 211.165(f)Failing drug products not rejected
- 21 CFR 211.84(d)(6)Objectionable microbiological contamination
- 21 CFR 211.84(e)Rejecting When Specifications Not Met
- 21 CFR 211.166(a)Results not used for expiration dates, storage cond.
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Eosera, Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| March 20, 2026 | Not classified | Dallas District Office | Drug Quality Assurance |
| April 28, 2025 | Not classified | Dallas District Office | Drug Quality Assurance |
| March 1, 2022 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Eosera, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.